TYRA250516P25000
- 9.50
- 0.000.00%
TYRA BIOSCIENCES, INC. Newsroom
Northrop Grumman Posts Downbeat Results, Joins Halliburton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight
Why Penguin Solutions Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $30
TD Cowen Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating
Tyra Biosciences Advances Precision Medicine Pipeline
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $33
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $28
We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth
Tyra Biosciences Price Target Lowered to $28 From $29 at BofA
TYRA BIOSCIENCES, INC. | 10-K: FY2024 Annual Report
Tyra Biosciences Reports Q4 EPS (43c) Vs. (53c) Last Year
TYRA BIOSCIENCES, INC. | 8-K: Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
Express News | Tyra Biosciences: Cash, Cash Equivalents, and Marketable Securities of $341.4 Mln at Ye 2024; Runway Through at Least 2027
Express News | Tyra Biosciences Q4 Operating Expenses USD 29.744 Million
Express News | Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
Express News | Tyra Biosciences Q4 Basic EPS USD -0.43 Vs. IBES Estimate USD -0.48
Express News | Tyra Biosciences Q4 Operating Income USD -29.744 Million Vs. IBES Estimate USD -29.7 Million
Press Release: Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights